Biogen Idec considering sale of cancer drug

Biogen Idec touted significant growth in its third quarter income and said it is evaluating "strategic options" for its older cancer drug Zevalin that includes a possible sale of the therapy. The growth in revenue--from $596 million a year ago to $703 million this past quarter--was due largely to the return of Tysabri and increased revenue from Rituxan, which has emerged as the "gold standard" in the treatment of rheumatoid arthritis.

- here's a report on Biogen Idec from the Boston Business Journal